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Abstract
Introduction: Sildenafil	has	been	evaluated	in	>16	000	men	with	erectile	dysfunction	
(ED) in double- blind, placebo- controlled trials.
Aim: To	assess	efficacy	and	safety	of	sildenafil	in	ED	by	ethnicity	(white,	black	Asian)	
and	age	(≤45,	46-	60,	≥61	years).
Methods: Data were pooled from 38 double- blind, placebo- controlled, flexible- dose 
trials. Most had starting sildenafil doses of 50 mg once daily, ~1 hour before sexual 
activity, with adjustment to 100 or 25 mg as needed.
Main Outcome Measures: Change from baseline in International Index of Erectile 
Function erectile function (IIEF- EF) domain score assessed with analysis of covariance 
and	 a	 Global	 Assessment	 Question	 (GAQ;	 “Did	 the	 treatment	 improve	 your	 erec-
tions?”) at endpoint assessed with logistic regression analysis.
Results: 4120 and 3714 men received sildenafil and placebo, respectively (2740 and 
2671	White;	407	and	385	Black;	973	and	658	Asian).	For	sildenafil	vs.	placebo	groups,	
overall	treatment	differences	for	IIEF-	EF	domain	and	GAQ	were	significant	for	each	
ethnic and age group (P<.0001); significant treatment- by- ethnicity and treatment- by- 
age interactions were also observed for change in IIEF- EF domain scores (P<.05), with 
differences	 significantly	 greater	 for	 White	 vs.	 Black	 (P<.0001),	 White	 vs.	 Asian	
(P=.0163),	and	Asian	vs.	Black	(P=.0036)	men.	A	significant	treatment-	by-	ethnicity	in-
teraction	was	observed	for	GAQ	(P=.0004).	The	OR	comparison	for	GAQ	was	signifi-
cantly greater (P=.0001)	 with	 sildenafil	 vs.	 placebo	 in	 White	 (OR=11.2)	 or	 Asian	
(OR=12.4)	men	vs.	Black	men	(OR=5.1).	Adverse-	event	rates	were	generally	similar,	
with some age variations.
Conclusions: Sildenafil	 is	effective	and	well-	tolerated	regardless	of	ethnicity	or	age;	
however, treatment effects can vary.
1  | INTRODUCTION
Erectile dysfunction (ED), the persistent inability to achieve and/or 
maintain erections sufficient for satisfactory sexual performance,1 
is a multifactorial condition that is associated with age, comorbid 
systemic diseases (eg, cardiovascular disease [CVD], hypertension 
[HTN], diabetes and depression), certain therapeutic medications 
(eg, antihypertensives, antidepressants and vasodilators) and vari-
ous endocrine, neurological and psychological factors.2	 With	 the	
availability in 1998 of sildenafil, the first oral medication for the 
treatment	of	ED,	the	management	of	ED	entered	a	new	era.	Sildenafil	
is an effective and well- tolerated oral agent that is recommended as 
a first- line therapy for ED 3,4 based on data from extensive double- 
blind,	 placebo	 (PBO)-	controlled	 trials	 in	 more	 than	 >16	000	 men	
with ED and nearly 20 years of use in clinical practice. The efficacy 
and safety data collected during the clinical trials of sildenafil provide 
a database for investigating factors that may influence and aid in the 
management of ED in clinical practice. For example, the efficacy and 
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safety of sildenafil vs. placebo according to patient age recently were 
assessed	 in	 11	364	men	with	 ED	 using	 data	 from	48	 randomised,	
double- blind, placebo- controlled, flexible- dose sildenafil trials.5 The 
results of this pooled analysis indicated that sildenafil is a clinically 
effective and well- tolerated treatment for ED regardless of patient 
age,	including	those	aged	≥75	years.	In	the	current	article,	data	from	
38 randomised, double- blind, placebo- controlled, flexible- dose, 
sildenafil trials were used to evaluate the effects of patient ethnicity 
and age on the efficacy and safety of sildenafil for the treatment of 
ED.
2  | METHODS
Of the 74 double- blinded, placebo- controlled, sildenafil clinical trials 
included in a Pfizer clinical data repository, 38 trials had a flexible- 
dose design, included the self- reported ethnicity of the enrolled men, 
and collected baseline and endpoint data for the International Index 
of Erectile Function (IIEF) 6 for men with ED who were randomised 
to sildenafil or placebo; 37 of these 38 flexible- dose trials collected 
Global	Assessment	Question	(GAQ;	“Did	the	treatment	improve	your	
erections?”) data at endpoint. In the present post hoc analysis, data 
were pooled from these 38 double- blind, placebo- controlled, flexible- 
dose trials to assess the efficacy and safety of sildenafil according 
to ethnicity and age. The starting sildenafil dose was 50 mg, to be 
taken approximately 1 hour before sexual activity but not more than 
once daily, with subsequent dose adjustment to 100 mg or 25 mg as 
needed. The majority of the trials included a 12- week treatment pe-
riod	and	enrolled	men	with	ED	of	3-	6-	months’	duration	who	were	in	
a stable heterosexual relationship. Men taking nitrate therapy or nitric 
oxide donors and those with severe cardiac failure, unstable angina, or 
recent stroke or myocardial infarction were excluded from enrolment. 
Each study was conducted in accordance with Good Clinical Practice 
Guidelines	and	the	Declaration	of	Helsinki.	All	trial	protocols	were	ap-
proved by appropriate local ethics committees or institutional review 
boards. Each subject provided written informed consent before trial 
enrolment.
The data were pooled for the overall population and also stratified 
by	self-	reported	ethnicity	(white,	black,	and	Asian)	and	by	age	at	base-
line	 (≤45,	46-	60,	 and	≥61	years).	 Efficacy	 analyses	 included	 all	men	
with	ED	who	were	randomised	to	treatment	and	had	baseline	and	≥1	
postbaseline assessment of the IIEF efficacy outcome or a response to 
the	GAQ	at	endpoint.	Safety	analyses	 (ie,	 treatment-	related	adverse	
events) included all randomised men who received at least one dose of 
study medication. Treatment efficacy was assessed based on patient- 
reported scores for the IIEF erectile function (IIEF- EF) domain (score 
range: 1- 30, with lower scores indicating greater ED severity), IIEF 
question	3	(Q3:	achieving	erection;	score	range:	0-	5)	and	IIEF	question	
4	(Q4;	maintenance	of	erection;	score	range:	0-	5)	at	baseline	and	end-
point (38 trials),6	and	a	Global	Assessment	Question	(GAQ:	“Did	the	
treatment	 improve	your	erections?”)	 at	 endpoint	 (37	 trials).	Adverse	
events occurring during each study and up to 7 days after the last dose 
of study medication were reported.
For	each	IIEF	outcome,	an	analysis	of	covariance	(ANCOVA)	model	
was applied to the change from baseline to endpoint (or termination with 
last-	observation-	carried-	forward	[LOCF]	method).	The	ANCOVA	model	
included baseline value, study, treatment, age group, ethnic group, three 
comorbidity indicators (CVD/HTN, depression, and diabetes), interac-
tion of treatment by age group, interaction of treatment by ethnic group, 
and interaction of treatment by ethnic and age group. For each IIEF 
outcome,	the	least	squares	(LS)	mean,	the	standard	error	(SE)	of	the	LS	
mean, and P values for the treatment comparison between sildenafil and 
PBO	and	a	type	3	test	for	main	effects	and	the	interaction	of	treatment	
by age and/or ethnic group were reported. In addition, the treatment dif-
ference was compared between age groups and between ethnic groups 
separately.	For	the	GAQ,	a	 logistic	 regression	model	was	applied.	The	
logistic regression analysis included study, treatment, age group, ethnic 
group, three comorbidity indicators (CVD/HTN, depression and diabe-
tes), interaction of treatment by age group, interaction of treatment by 
ethnic group, and interaction of treatment by ethnic and age group. The 
odds	ratio	(OR;	exponentiated	estimate)	for	sildenafil	vs.	PBO,	the	95%	
confidence interval (CI) of the OR, the P value for the treatment compar-
ison, and the likelihood- ratio statistic for the type 3 test for main effects 
and interactions were assessed. In addition, the treatment difference OR 
was compared between age groups and between ethnic groups sepa-
rately.	All	statistical	tests	were	2-	sided	with	a	5%	level	of	significance.	
No adjustment was made for multiple comparisons.
3  | MAIN OUTCOME MEASURES
Patient- reported quantitative scores for the IIEF erectile function 
domain,	Q3	 (achieving	 erection),	 and	Q4	 (maintenance	 of	 erection)	
What’s known
Sildenafil	is	a	well-	tolerated	and	effective	first-	line	therapy	for	
erectile dysfunction, as evidenced by its almost two decades 
of	use	in	clinical	practice.	A	large	body	of	sildenafil	clinical	trial	
data provides important information that can be used to facili-
tate the clinical management of patients with erectile dys-
function. Pooled analyses from 48 randomised, double- blind, 
placebo- controlled, flexible- dose sildenafil trials showed the 
efficacy and tolerability of sildenafil are unaffected by age.
What’s new
The treatment of erectile dysfunction with a flexible- dose of 
sildenafil was effective and well- tolerated vs. placebo treat-
ment	in	white,	black	and	Asian	men,	regardless	of	their	eth-
nic	 background.	 Although	men	 of	 all	 ages	 and	 ethnicities	
achieve a significant treatment effect with sildenafil vs. pla-
cebo, there are some variations in the efficacy and safety of 
sildenafil vs. placebo as a result of treatment- by- ethnicity 
and treatment- by- age interactions.
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at baseline and endpoint, together with the qualitative yes or no re-
sponse	to	the	GAQ	at	endpoint,	were	the	main	outcome	measures.
4  | RESULTS
4.1 | Patients
A	total	of	7834	men	were	included	in	the	present	post	hoc	analysis,	with	
4120	men	treated	with	sildenafil	 (white:	2740;	black:	407;	Asian:	973)	
and	3714	men	treated	with	PBO	(white:	2671	black:	385;	Asian:	658).	
The mean age and IIEF scores at baseline within each ethnicity group and 
within each age group were comparable for men treated with sildenafil 
and	men	treated	with	PBO	(Table	1).	The	mean	duration	of	ED	at	base-
line was 4- 5 years across the three ethnicity groups. The mean scores at 
baseline	for	the	IIEF-	EF	domain,	IIEF	Q3	and	IIEF	Q4	generally	decreased	
with increasing age in each ethnic group. The modal dose of sildenafil 
during these flexible- dose trials was predominantly 100 mg in each eth-
nic	group	(white:	64%;	black:	62%;	Asian:	58%)	and	in	each	age	group	
(≤45	years:	49%	to	61%;	46-	60	years:	56%-	69%;	≥61	years:	56%-	65%).
4.2 | Efficacy outcomes
Based	on	type	3	tests	from	the	ANCOVA	model	analysing	quantita-
tive IIEF outcomes, significant treatment- by- age and treatment- by- 
ethnicity interactions were observed for the change from baseline 
in	 IIEF-	EF	domain,	Q3	(achieving	erection),	and	Q4	(maintenance	of	
erection) scores (all P<.05; Table 2). In addition, significant treatment 
differences were observed in the change from baseline in the IIEF- EF 
domain,	Q3,	and	Q4	scores	between	men	with	vs.	men	without	CVD/
HTN (P<.05) and men with vs. men without diabetes (P<.0001), but not 
between men with vs. men without depression (P≥.2463).	Treatment	
differences	were	highest	 in	men	aged	≥61	years	and	 lowest	 in	men	
aged	≤45	years.	The	treatment	difference	was	the	greatest	 in	white	
men and the lowest in black men.
All	treatment	differences	significantly	favoured	sildenafil	vs.	PBO	
in the change from baseline to endpoint in the IIEF- EF domain score 
for each ethnic, age and ethnic- age group (all P values <.02; Table 3). 
Within	the	three	ethnic	groups,	the	treatment	comparison	for	sildena-
fil	vs.	PBO	in	IIEF-	EF	domain	scores	was	significantly	greater	for	white	
TABLE  1 Patient characteristics at baseline according to ethnic and age groups
Placebo Sildenafil
White Black Asian White Black Asian
Mean	(SD)	age,	years	Range n=2671 
55.9 (11.0) 
18- 89
n=385 
52.7 (10.8) 
23- 81
n=658 
52.2 (11.3) 
24- 78
n=2740 
56.3	(10.9) 
19- 87
n=407 
53.4 (9.5) 
21- 78
n=973 
50.6	(11.9) 
24-	86
≤45	years n=450 
38.7 (5.7) 
18- 45
n=94 
8.4 (5.7) 
23- 45
n=190 
38.2 (5.3) 
24- 45
n=419 
38.6	(5.7) 
19- 45
n=77 
39.2 (5.0) 
21- 45
n=350 
37.7 (5.7) 
24- 45
46-	60	years n=1245 
53.4 (4.2) 
46-	60
n=204 
53.2 (4.2) 
46-	60
n=300 
43.4 (4.3) 
46-	60
n=1299 
53.5 (4.2) 
46-	60
n=234 
53.1 (4.1) 
46–60
n=401 
53.3 (4.4) 
46-	60
≥61	years n=976 
67.1	(4.8) 
61-	89
n=87 
66.8	(4.8) 
61-	81
n=168 
66.0	(4.2) 
61-	78
n=1022 
67.2	(4.8) 
61-	87
n=96 
65.5	(3.4) 
61-	78
n=222 
66.1	(4.6) 
61-	86
Mean	(SD)	ED	duration,	y 4.7	(4.6) 4.6	(5.3) 4.1 (4.0) 4.6	(4.3) 4.1 (4.0) 4.1 (4.2)
Mean	(SD)	IIEF	score	at	baselinea
EF domaina
≤45	years 14.6	(6.9) 14.4	(6.0) 14.2	(4.6) 14.3 (7.0) 16.3	(6.2) 15.0 (4.2)
46-	60	years 12.6	(6.8) 13.8	(6.4) 12.6	(5.3) 12.7	(6.9) 13.1	(6.5) 13.5 (4.8)
≥61	years 10.9	(6.8) 11.6	(7.1) 12.2	(6.3) 10.9	(6.7) 12.0 (7.5) 12.2 (5.7)
Q3a
≤45	years 2.7	(1.6) 2.6	(1.5) 2.5 (1.3) 2.6	(1.6) 3.0 (1.5) 2.6	(1.3)
46-	60	years 2.3 (1.5) 2.6	(1.4) 2.1 (1.3) 2.3 (1.5) 2.3 (1.5) 2.3 (1.3)
≥61	years 1.9 (1.5) 1.9 (1.5) 2.0 (1.4) 1.9 (1.5) 2.0	(1.6) 1.9 (1.3)
Q4a
≤45	years 2.3 (1.4) 2.1 (1.3) 2.0 (1.1) 2.2 (1.5) 2.6	(1.2) 2.1 (1.1)
46-	60	years 1.9 (1.4) 2.2 (1.3) 1.8 (1.1) 1.9 (1.3) 2.1 (1.3) 1.9 (1.1)
≥61	years 1.6	(1.3) 1.8 (1.5) 1.8 (1.2) 1.6	(1.3) 1.8 (1.5) 1.8 (1.2)
ED,	erectile	dysfunction;	 IIEF,	15-	item	International	 Index	of	Erectile	Function;	SD,	standard	deviation.	Data	from	38	double-	blind,	placebo-	controlled,	
flexible- dose trials. aQ3=IIEF	question	3	(achieving	erection;	score	range	0-	5);	Q4=IIEF	question	4	(maintaining	erection;	score	range	0-	5);	EF	Domain=6-	
item erectile function domain (score range: 1- 30).
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vs. black men (P<.0001),	white	vs.	Asian	men	(P=.0163)	and	Asian	vs.	
black men (P=.0036).	Within	the	three	age	groups,	the	comparison	for	
sildenafil	vs.	PBO	 in	 IIEF-	EF	domain	scores	was	significantly	greater	
for	men	aged	≥61	years	vs.	men	aged	≤45	years	(P=.0103) and for men 
aged	46-	60	years	vs.	men	 aged	≤45	years	 (P=.0217).	 Similar	 signifi-
cant	results	were	observed	for	comparisons	in	IIEF	Q3	and	Q4	scores	
for	 sildenafil	vs.	 PBO	within	 the	 ethnicity	 and	 age	 groups	 (data	 not	
shown),	 except	 the	 treatment	 comparison	 between	white	 vs.	Asian	
men	was	not	significant	(Q3:	P=.8561;	Q4:	P=.8400).
The results of type 3 tests from the logistic regression analysis of 
the	 qualitative	GAQ	 indicated	 a	 significant	 treatment-	by-	ethnicity	 in-
teraction (P=.0004) and a non- significant treatment- by- age interaction 
(P=.5331)	(Table	2).	Significant	differences	were	observed	for	the	GAQ	
between men with vs. men without diabetes (P<.0001), but not between 
men with vs. men without CVD/HTN (P=.2049) or depression (P=.1368).
The	OR	for	sildenafil	vs.	PBO	on	the	GAQ	at	endpoint	was	signifi-
cant in each ethnic group and in each age group (all P<.0001; Table 4). 
The	ORs	 for	 sildenafil	 vs.	 PBO	were	 similar	 in	men	 aged	 ≤45	years	
(OR=7.9),	 46-	60	years	 (OR=8.9),	 and	 ≥61	years	 (OR=10.1).	 Each	
comparison between age groups was not significant. The ORs for 
sildenafil	vs.	PBO	in	white	men	(OR=11.2)	and	Asian	men	(OR=12.4)	
were greater than the OR for black men (OR=5.1). Treatment compar-
isons between ethnic groups were significant for white vs. black men 
(P=.0001)	and	for	Asian	vs.	black	men	(P=.0001).
4.3 | Adverse events
Treatment with sildenafil was well tolerated in each ethnic and age group. 
The	most	common	treatment-	related	adverse	events	(ie,	≥3%	incidence	
in either treatment group and with a greater incidence with sildenafil 
than with placebo) are listed in Table 5. Overall, treatment- related ad-
verse events were predominantly mild in severity. Headache was the 
most common treatment- related adverse event in white and black men, 
whereas flushing was the most common treatment- related adverse 
event	in	Asian	men.	In	men	aged	≤45	years,	the	incidence	of	treatment-	
related	headache	was	higher	in	black	men	(20.8%)	than	in	white	(13.4%)	
or	Asian	(12.6%)	men.	The	incidence	of	headache	was	slightly	higher	in	
white	men	than	in	black	or	Asian	men	in	the	46-	60-	year	and	≥61-	year	
age groups. Of note, flushing was not a common treatment- related ad-
verse event among black men in any age group.
TABLE  2 Change from baseline to endpoint in IIEF scoresa	and	improved	erections	at	endpoint	for	GAQb
Outcome
Overall treatment 
difference (Sildenafil 
vs. PBO)
Overall age 
group 
difference
Overall 
ethnic group 
difference
Treatment- by- age 
group interaction
Treatment- by- ethnic 
group interaction
Comorbidity 
effect
Study 
effect
IIEF Erectile 
function domain
P<.0001 P<.0001 P<.0001 P=.0242 (P<.0001) CVD/HTN: 
P=.0105 
Diabetes: 
P<.0001 
Depression: 
P=.2463
P<.0001
IIEF	Q3	(achieving	
erection)
P<.0001 P<.0001 P=.0001 P=.0411 P=.0002 CVD/HTN: 
P=.0170 
Diabetes: 
P<.0001 
Depression: 
P=.6146
P<.0001
IIEF	Q4	(maintaining	
erection)
P<.0001 P<.0001 P=.0231 P=.0439 P=.0003 CVD/HTN: 
P=.0004 
Diabetes: 
P<.0001 
Depression: 
P=.4884
P<.0001
GAQ	(“Did	the	
treatment improve 
your erections?”)
P<.0001 P<.0001 P<.0001 P=.5331 P=.0004 CVD/HTN: 
P=.2049 
Diabetes: 
P<.0001 
Depression: 
P=.1368
P<.0001
ANCOVA,	analysis	of	covariance;	GAQ,	global	assessment	question;	IIEF,	International	Index	of	Erectile	Function;	CVD/HTN,	cardiovascular	disease	and/
or	hypertension;	PBO,	placebo.	Data	from	38	(IIEF)	or	37	(GAQ)	double-	blind,	PBO-	controlled,	flexible-	dose	trials;	includes	only	men	with	baseline	and	
postbaseline	IIEF	scores	or	GAQ	data.	aSignificance	for	IIEF	outcomes	based	on	P	values	for	type	3	test	from	ANCOVA	model	with	baseline	value,	study,	
treatment, age group, ethnic group, three comorbidity indicators (CVD/HTN, depression and diabetes), treatment- by- age group interaction, treatment- by- 
ethnic	group	interaction	and	treatment-	by-	age	group-	ethnic	group	interaction	(2-	sided	at	5%	significance	level).	bSignificance	for	GAQ	based	on	likelihood	
ratio P values for type 3 analysis from logistic regression model with study, treatment, age group, ethnic group, three comorbidity indicators (CVD/HTN, 
depression and diabetes), treatment- by- age group interaction, treatment- by- ethnic group interaction, and treatment- by- ethnic group and age group inter-
action	(2-	sided	at	5%	significance	level).
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5  | DISCUSSION
In the current analyses, data for 7834 men from 38 randomised, 
double- blind, placebo- controlled, flexible- dose, sildenafil trials were 
used	to	evaluate	the	effects	of	patient	ethnicity	(white,	black	or	Asian)	
and	 age	 (≤45,	 46-	60,	 or	 ≥61	years)	 on	 the	 efficacy	 and	 safety	 of	
sildenafil for the treatment of ED. The results of this pooled analysis 
demonstrated	that	overall	treatment	differences	for	sildenafil	vs.	PBO	
for	the	IIEF-	EF	domain	and	the	GAQ	were	significant	for	each	ethnic	
and each age group (all P <.0001). However, significant treatment- 
by- ethnicity and treatment- by- age interactions were observed for 
the change from baseline in quantitative IIEF- EF domain scores with 
sildenafil	 vs.	 PBO	 (all	 P<.05).	 A	 significant	 treatment-	by-	ethnicity	
interaction also was observed for the treatment difference in the 
qualitative	GAQ	 (P=.0004). The types and incidences of treatment- 
related	adverse	events	were	generally	similar	in	white,	black	and	Asian	
men, with some variations among the three age groups. Overall, these 
results demonstrate the efficacy and safety of sildenafil in white, black 
and	Asian	men	in	all	three	age	groups,	with	some	variations	in	treat-
ment effects according to ethnicity and age.
The strengths of the current analyses of the efficacy of sildenafil 
are that the statistical models included a treatment- by- ethnicity in-
teraction and also adjusted for various ED- associated comorbidities 
2 that may have an effect on ED treatment responsiveness.7 The ef-
ficacy and safety data also were collected during trials with a similar 
double-	blind,	PBO-	controlled,	 flexible-	dose	design.	Furthermore,	ef-
ficacy results were assessed with both the quantitative change from 
Comparison (Sildenafil vs. PBO)
LS mean (SE) treatment 
difference 95% CI P Valuea
Overall 6.4	(0.2) 6.0-	6.9 <.0001
Ethnic groups
White 7.8 (0.2) 7.3- 8.2 <.0001
Black 4.8	(0.6) 3.8- 5.9 <.0001
Asian 6.7	(0.4) 6.0-	7.5 <.0001
Between	ethnic	groups
White	vs.	Black 2.9	(0.6) 1.8- 4.1 <.0001
White	vs.	Asian 1.0 (0.4) 0.2- 1.8 .0163
Black	vs.	Asian −1.9	(0.7) −3.2-	−0.6 .0036
Age	groups
≤45	years 5.5 (0.5) 4.6-	6.4 <.0001
46-	60	years 6.7	(0.3) 6.2-	7.3 <.0001
≥61	years 7.1 (0.4) 6.3-	7.9 <.0001
Between	age	groups
≤45	vs.	46–60	years −1.2	(0.5) −2.3-	−0.2 .0217
≤45	vs.	≥61	years −1.6	(0.6) −2.8-	−0.4 .0103
46–60	vs.	≥61	years −0.3	(0.5) −1.4-	0.7 .6645
Ethnic- age groups
White	≤45	years 8.5 (0.5) 7.6-	9.5 <.0001
White	46-	60	years 7.5 (0.3) 6.9-	8.0 <.0001
White	≥61	years 7.3 (0.3) 6.6-	7.9 <.0001
Black	≤45	years 2.7 (1.1) 0.6-	4.9 .0139
Black	46-	60	years 5.2 (0.7) 3.9-	6.5 <.0001
Black	≥61	years 6.6	(1.0) 4.6-	8.6 <.0001
Asian	≤45	years 5.2	(0.6) 4.0-	6.5 <.0001
Asian	46-	60	years 7.6	(0.5) 6.5-	8.6 <.0001
Asian	≥61	years 7.4 (0.7) 6.0-	8.8 <.0001
ANCOVA,	 analysis	 of	 covariance;	 CI,	 confidence	 interval;	 IIEF-	EF	 domain,	 International	 Index	 of	
Erectile	Function	erectile	function	domain;	LS,	least	squares;	PBO,	placebo.	Data	from	38	double-	blind.	
PBO-	controlled,	flexible-	dose	trials;	includes	only	men	with	baseline	and	postbaseline	IIEF-	EF	scores.	
aP	value	from	ANCOVA	model	with	baseline	value,	study,	treatment,	age	group,	ethnic	group,	three	
comorbidity indicators (CVD/HTN, depression and diabetes), treatment- by- age group interaction, 
treatment- by- ethnic group interaction, and treatment- by- ethnic group and age group interaction (2- 
sided	at	5%	significance	level).
TABLE  3 Treatment difference 
(sildenafil	vs.	PBO)	for	the	change	from	
baseline to endpoint in IIEF- EF domain 
score in ethnic, age and ethnic- age groups
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baseline	 in	 IIEF	 scores	and	 the	qualitative	GAQ.	Possible	 limitations	
include that the 38 clinical trials enrolled only men with ED who did 
not have certain prespecified concomitant diseases and those who 
were in a stable heterosexual relationship. Therefore, the results may 
not reflect those for all men with ED.
It is important to evaluate the efficacy and safety of treatments 
for ED in men from various ethnic and age populations because dif-
ferent ethnic and age groups have different prevalence rates of 
ED- associated comorbid diseases and other risk factors for ED. For 
example,	 in	 the	United	States,	 the	 age-	adjusted	prevalence	of	HTN	
is greater in blacks than in whites 8 and the age- adjusted prevalence 
of	diabetes	is	higher	in	blacks	or	Asians	than	in	whites.9 Furthermore, 
the cultural and religious beliefs of different ethnic groups can have 
an impact on the diagnosis and treatment- seeking behaviour of men 
with ED.
Several	 small-	scale,	 PBO-	controlled	 studies	 of	 the	 efficacy	 and	
safety of sildenafil previously were conducted in black men 10 and 
in	 Asian	 men	 11–15	 with	 ED.	 In	 246	 black	 American	 men	with	 ED	
evaluated	by	Young	et	al.	in	a	double-	blind,	PBO-	controlled,	flexible-	
dose	 trial,	 approximately	60%	 reported	HTN	and	28%	 reported	di-
abetes.10	After	 6	weeks	 of	 treatment,	 IIEF-	EF	 domain,	Q3,	 and	Q4	
scores and the percentage of men indicating improved erections on 
the	GAQ	were	significantly	greater	with	sildenafil	vs.	PBO.	Treatment	
with	 sildenafil	was	well-	tolerated	 in	black	men,	with	only	22	 (18%)	
men experiencing treatment- related adverse events.10	 Four	 PBO-	
controlled studies assessing flexible- dose sildenafil for the treat-
ment	of	ED	 in	Asian	men	from	Malaysia/Singapore/the	Philippines,	
Thailand, Taiwan, or Korea (sample size range: 125- 254 men) demon-
strated	 significant	 improvements	 in	 IIEF-	EF	 domain,	 Q3,	 and	 Q4	
scores	and	significantly	 improved	erections	on	the	GAQ	with	silde-
nafil	vs.	 PBO	after	 8-	12	weeks	 of	 treatment.11–14 The incidence of 
treatment- related adverse events in these four studies ranged from 
23%	to	56%	in	the	sildenafil	group	and	from	10%	to	21%	in	the	PBO	
group; all or most adverse events in the sildenafil group were mild 
in	nature.	Another	small-	scale,	6-	week,	PBO-	controlled,	flexible-	dose	
study evaluated the efficacy and safety of sildenafil in 155 men from 
Malaysia,	Thailand	and	Singapore	with	ED	and	1	or	more	comorbid-
ities (ie, mild- moderate HTN, diabetes and dyslipidaemia).15 Despite 
the increased cardiovascular risk associated with one or more co-
morbidities,	Asian	men	with	ED	 treated	with	 sildenafil	 for	 6	weeks	
demonstrated	significant	improvements	in	IIEF-	EF,	Q3	and	Q4	scores	
and a significantly greater percentage reported improved erections 
on	the	GAQ	compared	with	PBO.	The	incidence	of	treatment-	related	
adverse	events	was	10%	in	the	sildenafil	group	and	10%	in	the	PBO	
group.15
The results of the present analysis of 7834 men provide strong val-
idation	of	the	efficacy	and	safety	of	sildenafil	vs.	PBO	in	the	treatment	
of	ED	in	white,	black	and	Asian	men,	regardless	of	age.	Comparisons	
between different ethnic and age groups indicate some variations in 
efficacy outcomes and adverse events, but each group demonstrates a 
significant	treatment	difference	favouring	sildenafil	vs.	PBO.	Although	
individual patients may have different ethnic backgrounds, different 
ages and different concomitant diseases, the clinical evidence indi-
cates that sildenafil significantly improves erectile function and is a 
well- tolerated treatment option for men with ED.
6  | CONCLUSIONS
Sildenafil	is	an	effective	and	well-	tolerated	treatment	for	ED	regard-
less of ethnicity or age. However, sildenafil treatment effects can vary 
with patient ethnicity and age.
TABLE  4 Treatment	difference	(sildenafil	vs.	PBO)	for	the	
percentage	of	men	with	improved	erections	on	GAQ	in	ethnic,	age	
and ethnic- age groups
Comparison (Sildenafil vs. 
PBO)
Odds ratio 
for treatment 
difference 95% CI P value
Overall 8.9 7.6-	10.5 <.0001
Ethnic groupsa
White 11.2 9.5- 13.2 <.0001
Black 5.1 3.5- 7.4 <.0001
Asian 12.4 9.5-	16.1 <.0001
Between	ethnic	groupsb
White	vs.	Black 2.2 1.5- 3.3 .0001
White	vs.	Asian 0.9 0.7- 1.2 .5354
Black	vs.	Asian 0.4 0.3- 0.7 .0001
Age	groupsa
≤45	years 7.9 5.7- 10.8 <.0001
46-	60	years 8.9 7.2- 11.0 <.0001
≥61	years 10.1 7.5-	13.6 <.0001
Between	age	groupsb
≤45	vs.	46-	60	years 0.9 0.6-	1.3 .5219
≤45	vs.	≥61	years 0.8 0.5- 1.2 .2624
46-	60	vs.	≥61	years 0.9 0.6-	1.3 .5032
Ethnic- age groupsa
White	≤45	years 16.7 11.5- 24.3 <.0001
White	46-	60	years 10.0 8.2- 12.2 <.0001
White	≥61	years 8.5 6.8-	10.7 <.0001
Black	≤45	years 3.2 1.5-	6.8 .0024
Black	46-	60	years 5.4 3.4-	8.6 <.0001
Black	≥61	years 7.6 3.7- 15.3 <.0001
Asian	≤45	years 9.1 5.9- 14.0 <.0001
Asian	46-	60	years 13.0 8.8- 19.2 <.0001
Asian	≥61	years 16.0 9.5-	26.9 <.0001
CI,	confidence	interval;	GAQ,	Global	assessment	question;	PBO,	placebo.	
Data	 from	37	double-	blind.	PBO-	controlled,	 flexible-	dose	trials;	 includes	
only	men	with	GAQ	data	at	endpoint.	aLiklihood ratio P value for type 3 
analysis from logistic regression model with study, treatment, age group, 
ethnic group, three comorbidity indicators (CVD/HTN, depression, and 
diabetes), treatment- by- age group interaction, treatment- by- ethnic group 
interaction and treatment- by- ethnic group and age group interaction (2- 
sided	at	5%	significance	level).	bWithin-	group	P value based on a ratio of 
the	odds	ratios	for	treatment	difference	(sildenafil	vs.	PBO).
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Group
Adverse event, n (%)
PBO Sildenafil
Ethnic groups
White n=2671
Headache:	70	(2.6)
Flushing: 23 (0.9)
Dyspepsia: 9 (0.3)
n=2740
Headache: 323 (11.8) 
Flushing:	266	(9.7) 
Dyspepsia:	100	(3.6)
Black n=385
Headache: 8 (2.1)
n=407
Headache:	46	(11.3)
Asian n=658
Flushing: 20 (3.0) 
Headache:	26	(4.0) 
Dizziness: 19 (2.9) 
Nasal	congestion:	4	(0.6)
n=973
Flushing: 124 (12.7) 
Headache:	69	(7.1) 
Dizziness: 55 (5.7) 
Nasal congestion: 31 (3.2)
Ethnic- age groups
White	≤45	years n=450
Headache: 14 (3.1) 
Flushing:	7	(1.6) 
Dyspepsia: 4 (0.9) 
Nasal congestion: 1 (0.2)
n=419
Headache:	56	(13.4) 
Flushing: 40 (9.5) 
Dyspepsia: 20 (4.8) 
Nasal congestion: 14 (3.3)
Black	≤45	years n=94
Headache: 2 (2.1) 
Dyspepsia: 0
n=77
Headache:	16	(20.8) 
Dyspepsia: 3 (3.9)
Asian	≤45	years n=190
Flushing:	5	(2.6) 
Headache: 8 (4.2) 
Dizziness: 7 (3.7)
n=350
Flushing:	44	(12.6) 
Headache:	23	(6.6) 
Dizziness: 20 (5.7)
White	46–60	years n=1245
Headache: 33 (2.7)
Flushing: 10 (0.8)
Dyspepsia: 1 (<0.1)
n=1299
Headache:	161	(12.4) 
Flushing:	125	(9.6) 
Dyspepsia:	47	(3.6)
Black	46–60	years n=204
Headache: 4 (2.0)
n=234
Headache: 23 (9.8)
Asian	46–60	years n=300
Headache: 9 (3.0) 
Dizziness:	6	(2.0) 
Nasal congestion: 3 (1.0)
n=401
Headache: 29 (7.2) 
Dizziness: 20 (5.0) 
Nasal congestion: 14 (3.5)
White	≥61	years n=976
Headache: 23 (2.4) 
Flushing:	6	(0.6) 
Dyspepsia: 4 (0.4)
n=1022
Headache:	106	(10.4) 
Flushing: 101 (9.9) 
Dyspepsia: 33 (3.2)
Black	≥61	years n=87
Headache: 2 (2.3)
n=96
Headache: 7 (7.3)
Asian	≥61	years n=168
Headache: 9 (5.4) 
Dizziness:	6	(3.6) 
Palpitations:	1	(0.6)
n=222
Headache: 17 (7.7) 
Dizziness:	15	(6.8) 
Palpitations: 7 (3.2)
PBO,placebo.	Data	from	38	double-	blind,	PBO-	controlled,	flexible-	dose	trials.	aTreatment- related ad-
verse	events	occurring	 in	≥3%	of	men	 in	either	 treatment	group	and	with	a	greater	 incidence	with	
sildenafil than with placebo.
TABLE  5 Most common treatment- 
related adverse eventsa in ethnic and 
ethnic- age groups
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